Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06216600

Women Focused Encounters for Resilience Independence Strength and Eudaimonia

The goal of this combination Type 1 hybrid and observational study is to evaluate the impact of a peer delivered intervention of acceptance and commitment therapy (ACT) + exercise + social support to address the substance (ab)use, violence, and AIDS/HIV (SAVA) to improve medication adherence for women living with HIV (WLWH). This intervention will be implemented by community based organizations that focus on WLWH across four counties. The main question it aims to answer are:

* Will peer provision of ACT, exercise, and social support improve medication adherence for WLWH? * Will community based organizations be able to sustain the intervention after research is completed, and what changes will need to be made to sustain the intervention.

Recruiting

Interested in participating?

Request Info

Key information

About this study

In the U.S. women living with HIV (WLWH) are less likely to engage in HIV care, be on antiretroviral therapy (ART), and achieve sustained viral suppression compared to men. The Substance (Ab)use, Violence/trauma, and HIV/AIDS (SAVA) syndemic is proposed to primarily contribute to gender-based differences in HIV outcomes.To meaningful address SAVA requires interventions that focus on each epidemic and transdiagnostic processes (shared mediators) including mood (depression/anxiety), negative beliefs and thoughts about HIV, and loneliness. The Women focused Encounters for Resilience, Independence, Strength, and Eudaimonia (WE RISE) intervention addresses SAVA by employing peer navigator (PN) delivered group-based acceptance and commitment therapy (ACT) + exercise + empathetic social support.

The goal of this proposal is to evaluate and implement WE RISE for WLWH across four sites in Ending the HIV Epidemic (EHE) jurisdictions (San Diego, CA; Charlotte, NC; Atlanta, GA and Los Angeles, CA). This study is guided by a study advisory board (SAB) of 12 women living with and/or otherwise affected by HIV.

At each site peers will be trained at the University of California San Diego (UCSD) to provide ACT, exercise and social support through didactic and experiential experiences and a workbook that guides them through the intervention. WE RISE delivery will be monitored by experts at UCSD and peers provided feedback through 6 months to encourage the development of mastery.

The first phase of WE RISE is a type 1 hybrid study that will involve randomizing participants 1:1 to the WE RISE intervention or a local curated list of resources that focus on providing HIV care, therapy, exercise and social support. All participants in this phase will undergo assessments (HIV adherence, trauma symptoms, substance use, depression, anxiety, loneliness and others) at weeks 0, 8 (end of intervention), 24 and 48. All participants in this arm will also receive a Fitbit to track objective activity (e.g. step counts).

This phase will pursue the following Aims:

Aim 1: Evaluate short (week 8) and longer term (weeks 12, 24) effectiveness of WE RISE on HIV (↑ ART adherence, ↑ continuous viral suppression), trauma (↓ trauma symptoms), substance use (↓ days and amount of substance use) and transdiagnostic factors such as mood (↓depression, ↓anxiety), stigma and loneliness.

Aim 2: Document the WE RISE implementation process by characterizing reach, effectiveness, adoption, implementation and maintenance (RE-AIM) by site for 24 weeks.

Phase 2 of WE RISE is an observational study that will focus on sustainability of WE RISE once research funding is completed. We will encourage our partnering community based organizations to adapt WE RISE as they see fit to enable them to continue to provide the intervention. Participants will undergo the same assessment schedule as in phase 1. In this phase, the study team will continue to observe and document the intervention for adaptations made and persistence of intervention fidelity.

This phase will focus on Aim 3.

Aim 3: Transcreate alternate or additional IS that address site specific barriers and facilitators to optimize the effectiveness, maintenance and broader dissemination of WE RISE at 24 weeks while documenting the implementation process (RE-AIM) and site-specific adaptations using the Framework for Recording Adaptations and Modifications-Enhanced (FRAME) through 48 weeks.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Is a woman
  • Able to read and understand English
  • Able to participate in a low intensity exercise program
  • HIV-seropositive
  • At risk substance use (any illegal or unprescribed drug), tobacco, marijuana or alcohol use (four or more drinks in one day or 8 or more in one week).
  • Reports missing more ART doses than previous months, or > 5 in a month, or has a detectable HIV viral load
  • Experienced interpersonal violence
  • Able and willing to provide informed consent

Exclusion criteria

  • Unwilling to participate in video record sessions (used to evaluate the quality of the intervention)
  • Enrolled in hospice
  • Not willing or not able to comply with study advisory board group participation agreement.

Treatment and study plan

Acceptance and Commitment Therapy (ACT)

Behavioral

Participants will undergo ACT in combination with exercise and social support.

Body weight circuit training

Behavioral

Participants will learn and undergo body weight circuit training in combination with ACT and social support.

Empathetic social support

Behavioral

Study participants will participate in empathetic social support

Control - list of resources

Other

A local list of resources to access exercise, therapy and social support will be provided.

Primary outcomes

  1. Antiretroviral therapy (ART) adherence by drug levels

    Time frame: Weeks 0, 8, 24 and 48.

    All participants will undergo testing for ART in hair samples

Secondary outcomes

  1. Antiretroviral therapy (ART) adherence by visual analog scale

    Time frame: Weeks 0, 8, 24 and 48.

    Self reported measure of adherence on a scale (score range 0 to 100 higher scores indicate higher adherence)

  2. Generalized Anxiety Disorder-7

    Time frame: Weeks 0, 8, 24 and 48.

    Measure of anxiety (score range 0 to 21, sum of items, 0-4 minimal anxiety, 5-9 mild anxiety, 10-14 moderate anxiety, 15-21 severe anxiety)

  3. Patient Health Questionnaire - 9

    Time frame: Weeks 0, 8, 24 and 48.

    Measure of depression (score range 0-27, sum of items, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, 20-27 severe depression)

  4. Timeline follow back substance use

    Time frame: Weekly during weeks 0-8, 24 and 48.

    Recall of substance use in the past week

  5. International trauma questionnaire

    Time frame: Weeks 0, 8, 24 and 48.

    Provides two components of scoring and interpretation: 1) categorical scoring for the diagnosis of post traumatic stress disorder, PTSD (two or more question 1 or 2, two or more question 3 or 4, two of more question 5 or 6, two or more question 7,8,9) and complex post traumatic stress disorder, CPTSD (two or more question 10 or 11, two or more questions 12 or 13, two or more questions 14 or 15, two or more questions 16,17,18). 2) Dimensional scores from 0 to 24 (higher scores indicate higher symptom severity) are also presented for the two subscales. For PTSD sum items 1 to 6, for disturbances of self organization sum items 10 to 15.

Other outcomes

  1. HIV Stigma Scale 12-short form

    Time frame: Weeks 0, 8, 24 and 48.

    Evaluates HIV stigma (scale ranges 12-48, sum of all items, higher scores indicate higher internalization of stigma)

  2. Loneliness (UCLA-3 item)

    Time frame: Weeks 0, 8, 24 and 48.

    Three item question about loneliness (range 1-9, score is sum of all items, higher score indicates higher loneliness)

  3. Fitbit data

    Time frame: Weeks 0, 8, 24 and 48.

    average step counts in past 2 weeks

Study contacts

Contact information is provided by the study sponsor or research team.

Helene Le

CONTACT

[email protected]

619-543-3116

Liliana Harkness

CONTACT

[email protected]

619-543-4753

Sponsors and collaborators

Lead sponsor

University of California, San Diego

Other

Collaborators

  • APLA Health
  • By His Stripes Wellness Center
  • Christie's Place
  • Sister Love

Registry information

Acronym: WE RISE

Important dates

Study start
2024
Primary completion
2027
Study completion
2028
First posted
Jan 22, 2024
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.